NCT04024865View on ClinicalTrials.gov

Domperidone and Risk of Serious Cardiac Events in Postpartum Women

CompletedOBSERVATIONAL
Enrollment

184,929

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Ventricular TachyarrhythmiaSudden Cardiac DeathLactationBreast Feeding
Interventions
DRUG

Domperidone

Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.

DRUG

No domperidone

Women with no prescription for domperidone during the six months following delivery.

Trial Locations (1)

H3T1E2

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

Drug Safety and Effectiveness Network, Canada

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Canadian Network for Observational Drug Effect Studies, CNODES

OTHER

NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women | Biotech Hunter | Biotech Hunter